… There is no evidence on benefits or harms of inhaled steroids in COVID-19. It is essential …
-morbid use or continued administration of inhaled corticosteroids (ICS) affects the outcomes of …

… The large randomised clinical trials (RCTs) conducted at the … associated with the use of ICSs
in COPD [9]. In addition, several … in clinical trials for chronic obstructive pulmonary disease. …

… However, data from routine clinical practice indicate ICS … and risks of ICS use in COPD,
drawing on evidence from RCTs and … evidence for the effectiveness and safety of ICS in COPD, …

… of COPD. COPD has been previously described as a “corticosteroid-resistant” condition,
but current clinical trial evidence shows that selected COPD patients, namely those with …

… The relatively few data we have about the activity of ICSs in COPD patients from bronchial
biopsies, induced sputum, or bronchoalveolar lavage (BAL) — biological windows of proximal…

… Inhaled corticosteroids (ICSs) have been used widely in the maintenance therapy of …
Our results support previous evidence suggesting the existence of synergy among inhaled …

… Results of recent clinical trials and observational studies indicate that not all patients with
COPD benefit from the use of ICS. In particular, those patients with recurrent exacerbations and …

… –0.97) or chronic obstructive pulmonary disease (COPD) (0.46, 0.40–0.52). The most frequent
clinical signs were fever and cough. Conclusion: The clinical signs of hospitalized COVID-…

… corticosteroids) that no extant clinical data point to a benefit derived from corticosteroids for
… MERS-CoV) respiratory infections and therefore that corticosteroids should not be used as a …

… aim of this study was to provide a systematic synthesis of data useful in the daily clinical
practice to guide clinicians toward the optimal approach for the de-escalation of ICSs in COPD. …